MISSION
The mission of the Program on the Pharmacoepidemiology of Cardiovascular-Kidney-Metabolic Diseases (PROMISE) is to advance the understanding of the treatments for cardio-kidney-metabolic diseases in clinical practice, in order to inform medical prescribing and improve patient care.
WHAT WE DO & WHO WE ARE
We study utilization, safety, effectiveness, and cost-effectiveness of treatment strategies among patients with cardio-kidney-metabolic diseases in clinical practice, through the use of cutting-edge epidemiologic and statistical methods, leveraging one of the nation’s largest data repository of longitudinal healthcare data to conduct pharmacoepidemiologic research in cardio-kidney-metabolic diseases, including claims data for over 200 million lives, registries, and electronic health records, and innovative linkage of different databases. PROMISE includes a multidisciplinary team with expertise in pharmacoepidemiology, statistics, endocrinology, nephrology, cardiology, and obesity medicine, and trains the next generation of researchers in pharmacoepidemiology of cardio-kidney-metabolic diseases from around the world.
The mission of the Program on the Pharmacoepidemiology of Cardiovascular-Kidney-Metabolic Diseases (PROMISE) is to advance the understanding of the treatments for cardio-kidney-metabolic diseases in clinical practice, in order to inform medical prescribing and improve patient care.
WHAT WE DO & WHO WE ARE
We study utilization, safety, effectiveness, and cost-effectiveness of treatment strategies among patients with cardio-kidney-metabolic diseases in clinical practice, through the use of cutting-edge epidemiologic and statistical methods, leveraging one of the nation’s largest data repository of longitudinal healthcare data to conduct pharmacoepidemiologic research in cardio-kidney-metabolic diseases, including claims data for over 200 million lives, registries, and electronic health records, and innovative linkage of different databases. PROMISE includes a multidisciplinary team with expertise in pharmacoepidemiology, statistics, endocrinology, nephrology, cardiology, and obesity medicine, and trains the next generation of researchers in pharmacoepidemiology of cardio-kidney-metabolic diseases from around the world.
Check us out at ADA's 85th Scientific Session.
Click here for the schedule.
|
Division of Pharmacoepidemiology & Pharmacoeconomics
Department of Medicine Brigham & Women's Hospital and Harvard Medical School 1620 Tremont Street Suite 3030 Boston, MA 02120 |
|